What is the recommended dose of vitamin K2 (menaquinone‑7) when taken with vitamin D3, and are there any contraindications such as warfarin use?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Vitamin K2 (Menaquinone-7) Dosing and Contraindications with Vitamin D3

Vitamin K2 (menaquinone-7) is absolutely contraindicated in patients taking warfarin, as doses as low as 10 µg daily can significantly interfere with anticoagulation control and reduce INR by up to 40%. 1

Warfarin Interaction: The Critical Contraindication

The interaction between vitamin K2 (MK-7) and warfarin is dose-dependent and clinically significant:

  • MK-7 at 10 µg/day caused clinically relevant INR lowering in 40% of subjects
  • MK-7 at 20 µg/day affected 60% of subjects
  • MK-7 at 45 µg/day decreased INR and uncarboxylated factor II by approximately 40% 1

This is particularly concerning because typical retail MK-7 supplements contain 45-240 µg, well above the threshold for interference. The FDA warfarin label explicitly instructs patients to "maintain a consistent amount of vitamin K" and avoid drastic dietary changes 2. While this guidance primarily addresses vitamin K1 (phylloquinone), the evidence clearly demonstrates MK-7 has potent anticoagulant-antagonizing effects.

Current guidelines recommend stable vitamin K intake in warfarin patients to prevent INR fluctuations 3, but supplementation with MK-7 should be avoided entirely given the unpredictable individual responses.

Recommended Dosing When NOT on Warfarin

For patients without warfarin contraindication, the evidence supports specific dosing regimens:

For Cardiovascular Health (Coronary Artery Calcification)

The most robust recent evidence supports MK-7 720 µg/day combined with vitamin D3 25 µg/day 4. This 2026 DANCODE trial in 398 patients with severe coronary calcification (CAC ≥400 Agatston units) demonstrated:

  • Reduced CAC progression by 52 Agatston units over 24 months (p<0.001)
  • Attenuated calcified plaque volume progression by 8 mm³
  • Consistent benefit across sex and baseline CAC severity
  • No increase in noncalcified plaque volume

This represents the highest quality, most recent evidence for MK-7 dosing with vitamin D3.

For Bone Health

The evidence is less supportive. A 2021 trial using MK-7 375 µg/day with vitamin D3 38 µg/day and calcium 800 mg/day showed:

  • Successful carboxylation of osteocalcin (65% reduction in undercarboxylated form)
  • No benefit for bone mineral density, microarchitecture, or turnover markers over 3 years 5

This suggests MK-7 may not be effective for osteoporosis prevention despite theoretical mechanisms.

For Long COVID

A 2025 trial used MK-7 240 µg/day with vitamin D3 2000 IU/day and showed:

  • Improved RECOVER Long COVID Index
  • Reduced inflammatory markers and fungal translocation
  • Decreased number of symptoms 6

Practical Algorithm for MK-7 Use

Step 1: Screen for absolute contraindications

  • Current warfarin or vitamin K antagonist use → DO NOT USE MK-7
  • Coagulation disorders → Avoid

Step 2: Determine indication

  • Severe coronary calcification (CAC ≥400): MK-7 720 µg + D3 25 µg daily
  • Long COVID symptoms: MK-7 240 µg + D3 2000 IU daily
  • Osteoporosis/bone health: Not recommended based on current evidence

Step 3: Monitor vitamin D levels

  • Ensure adequate 25(OH)D levels (target >30 ng/mL)
  • The synergistic effect requires sufficient vitamin D3 7

Common Pitfalls to Avoid

  1. Assuming all vitamin K forms are equivalent: MK-7 has much longer half-life and greater bioavailability than K1, making it more potent for interfering with warfarin 1

  2. Using MK-7 in "stable" warfarin patients: Even with dose adjustment, the unpredictable individual responses (40-60% affected at low doses) make this unsafe 1

  3. Expecting bone benefits: Despite theoretical mechanisms, the 3-year RCT showed no benefit for BMD or microarchitecture 5

  4. Inadequate vitamin D co-supplementation: The cardiovascular benefits require adequate vitamin D3 (25 µg minimum) 4

The ESPEN guidelines note that vitamin K2 is synthesized by intestinal bacteria and contributes to requirements, but provide no specific MK-7 supplementation recommendations 8. The strongest evidence supports MK-7 720 µg with D3 25 µg for cardiovascular calcification, with absolute avoidance in warfarin users.

References

5
Research

The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2021

8
Guideline

espen micronutrient guideline.

Clinical Nutrition, 2022

Related Questions

Can a patient on carvedilol, lisinopril, empagliflozin, and atorvastatin safely continue a daily vitamin D3 supplement that contains 100 mg of vitamin K2, or should the vitamin K2 dose be reduced to the typical microgram range?
Should cholecalciferol (vitamin D3) be taken together with menaquinone‑7 (vitamin K2) in healthy adults, especially when using ≥1,000 IU daily or having risk factors for calcium‑related vascular calcification?
Can I take vitamin K2 (menaquinone) and vitamin D3 (cholecalciferol) with doxycycline (tetracycline antibiotic)?
How often should someone taking vitamin D (cholecalciferol) weekly take vitamin K2 (menaquinone)?
What are the indications for vitamin K?
Which infections can cause fever and new‑onset confusion in an adult?
Can embryo transfer be performed while the patient is undergoing antibiotic treatment for bacterial vaginosis?
What is the most common cause of hemolytic disease of the newborn?
What is the appropriate dose for treating impetigo in a child when flucloxacillin is unavailable?
How do I assess sodium and volume retention in a patient?
For a small child, is a 12‑hour dosing interval acceptable for antibiotics such as cefalexine or clindamycin instead of the usual 6‑ or 8‑hour schedule?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.